CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 2,370 enrolled
Drug / intervention
Plecanatidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01919697
NCT01919697Phase 3Completed
CompareCT.gov

An Open-Label Extension (OLE), Long-term Safety and Tolerability Study of Plecanatide in Patients With Chronic Idiopathic Constipation (CIC)

Bausch Health Americas, Inc.·interventional·Posted Aug 9, 2013·Updated Jul 2, 2019

In Brief

A Phase 3 clinical trial evaluating Plecanatide for Chronic Idiopathic Constipation. Completed, enrolled 2,370 participants across 220 sites in 2 countries.

Detailed Summary

This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Idiopathic Constipation
CountriesCanada, United States
CollaboratorsSyneos Health

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 9, 2013
Enrollment StartAug 1, 2013
Primary CompletionJan 1, 2016
Study CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 12.9 years ago

Interventions

Plecanatidedrug